These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18418814)

  • 21. OCH-mediated shift of Th1 and Th2 cytokines by NKT cells in mice with aplastic anemia.
    Qiao X; Xie X; Shi W; Tang J; Shao Y; Li F
    Med Oncol; 2015 Mar; 32(3):67. PubMed ID: 25691295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of NBD-alpha-galactosylceramide and its immunologic properties.
    Sakai T; Ehara H; Koezuka Y
    Org Lett; 1999 Aug; 1(3):359-61. PubMed ID: 10822576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis.
    Burdin N; Brossay L; Kronenberg M
    Eur J Immunol; 1999 Jun; 29(6):2014-25. PubMed ID: 10382765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
    Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
    J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and evaluation of 1,2,3-triazole containing analogues of the immunostimulant alpha-GalCer.
    Lee T; Cho M; Ko SY; Youn HJ; Baek DJ; Cho WJ; Kang CY; Kim S
    J Med Chem; 2007 Feb; 50(3):585-9. PubMed ID: 17266209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
    Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
    J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
    Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
    J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
    Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
    Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
    Berkers CR; Ovaa H
    Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of natural killer T cells in antitumor immunotherapy.
    Hong C; Park SH
    Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of acyl-chain- and galactose-6''-modified analogues of α-GalCer for NKT cell activation.
    Hsieh MH; Hung JT; Liw YW; Lu YJ; Wong CH; Yu AL; Liang PH
    Chembiochem; 2012 Jul; 13(11):1689-97. PubMed ID: 22730199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-18 time-dependently modulates Th1/Th2 cytokine production by ligand-activated NKT cells.
    Uchida T; Kinoshita M; Fukasawa M; Habu Y; Shinomiya N; Seki S
    Eur J Immunol; 2007 Apr; 37(4):966-77. PubMed ID: 17330820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The synthesis and in vivo evaluation of 2',2'-difluoro KRN7000.
    Leung L; Tomassi C; Van Beneden K; Decruy T; Trappeniers M; Elewaut D; Gao Y; Elliott T; Al-Shamkhani A; Ottensmeier C; Werner JM; Williams A; Van Calenbergh S; Linclau B
    ChemMedChem; 2009 Mar; 4(3):329-34. PubMed ID: 19137519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice.
    Hong S; Scherer DC; Singh N; Mendiratta SK; Serizawa I; Koezuka Y; Van Kaer L
    Immunol Rev; 1999 Jun; 169():31-44. PubMed ID: 10450506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock.
    Sireci G; La Manna MP; Di Sano C; Di Liberto D; Porcelli SA; Kronenberg M; Dieli F; Salerno A
    J Leukoc Biol; 2007 Mar; 81(3):607-22. PubMed ID: 17046969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity.
    Fujio M; Wu D; Garcia-Navarro R; Ho DD; Tsuji M; Wong CH
    J Am Chem Soc; 2006 Jul; 128(28):9022-3. PubMed ID: 16834361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total enantioselective synthesis and in vivo biological evaluation of a novel fluorescent BODIPY alpha-galactosylceramide.
    Vo-Hoang Y; Micouin L; Ronet C; Gachelin G; Bonin M
    Chembiochem; 2003 Jan; 4(1):27-33. PubMed ID: 12512073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
    Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
    Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.
    Fujii S; Shimizu K; Hemmi H; Fukui M; Bonito AJ; Chen G; Franck RW; Tsuji M; Steinman RM
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11252-7. PubMed ID: 16844772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.